Pharmaceutical industry – Page 28
-
BusinessMallinckrodt settles US opioid lawsuit
Firm will pay $35m over allegations it failed to report suspicious orders of controlled substances
-
OpinionMaking enough of a difference
What if the needle in the drug development haystack ends up being too small to be useful?
-
BusinessFDA approves first sickle cell drug in almost two decades
Glutamine-based drug is the first approved for children over 5
-
BusinessCelgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs
-
BusinessSilence Therapeutics and Alnylam in patent dispute
Suit alleges competitors need to license Silence patents relating to their drug cantidates
-
BusinessAmplifying intelligent drug design
This year’s Chemistry World Entrepreneur of the year is Andrew Hopkins of start-up Exscientia and the University of Dundee, UK
-
ResearchLilly pushes continuous drug production limits
Integrated flow synthesis and purification process for prexasertib meets high industry standards
-
BusinessFDA asks Endo to take pain drug off market
Request part of larger strategy to address opioid misuse in the US
-
ArticleSygnature Discovery
Sygnature Discovery is part of an innovative partnership to bolster the life science sector in Nottingham
-
BusinessJ&J licenses Protagonist’s inflammatory bowel peptide
Potential first-in-class treatment is just about to enter clinical trials
-
OpinionUnpicking a clinical trial death
A new study shows up off-target effects of a drug that proved deadly, and highlights the pitfalls of drug discovery
-
FeatureAccess to drugs: a failure of pharma?
Many people around the world are either unable to afford the drugs they need, or their conditions have not been addressed by pharma R&D. Sarah Houlton investigates
-
BusinessUS supreme court limits patent rights
Biotech industry is concerned that ruling will hit small companies
-
BusinessFirst biomarker-driven approval exemplifies cancer immunotherapy progress
Landmark decision is latest step in field’s impressive – but not wholly untroubled – advance
-
BusinessWillow promises new medicines
Investigating tree’s metabolites throws up much more than aspirin
-
OpinionDrug pricing must be more transparent
Pricing is a complex issue - how can we make it clearer?
-
BusinessEuropean Commission to investigate excessive drug pricing
Inquiry covers claims that Aspen Pharma’s price rises on five cancer treatments were unjustified
-
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
-
OpinionHow safe should drugs be?
What does spotting new risks in approved medicines say about how effective regulators are?
-
BusinessPatheon buyout brings Thermo into contract manufacturing
$7.2bn deal expands Thermo Fisher’s laboratory products and services segment